Core Insights - Olema Pharmaceuticals, Inc. has successfully closed an underwritten public offering of 11,500,000 shares of common stock at a price of $19.00 per share, generating gross proceeds of approximately $218.5 million before expenses [1]. Company Overview - Olema Oncology is a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer and other endocrine-driven cancers. The company is advancing a pipeline that includes its lead product candidate, palazestrant (OP-1250), which is currently in two Phase 3 clinical trials, and OP-3136, a KAT6 inhibitor in Phase 1 clinical study [5].